ArticleJournal of inflammation research2026
Glasgow Prognostic Score Predicts Hepatic Recompensation in Decompensated Primary Biliary Cholangitis: A Multicenter Cohort Study.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic liver disease progression is closely linked to systemic inflammatory responses and nutritional status. This study aimed to evaluate the prognostic value of the Glasgow Prognostic Score (GPS) system for predicting recompensation in patients with decompensated primary biliary cholangitis (PBC). Methods: This multicenter, retrospective cohort study enrolled patients with decompensated PBC admitted to seven hospitals between January 2014 and December 2023. The GPS, mGPS, and hs-mGPS were determined according to baseline CRP, hs-CRP, and ALB levels. The primary endpoint was the achievement of recompensation during follow-up (defined as biochemical response to UDCA, resolution of decompensating events, and stable improvement in liver function per Baveno VII criteria). Results: Of the 504 patients with decompensated PBC analyzed, the median age was 62 years (IQR: 53-69) and 81.5% (n=411) were women. Over a median follow-up of 31 months (IQR: 14-56), recompensation occurred in 136 patients (27.0%). Kaplan-Meier analysis confirmed that higher GPS, mGPS, and hs-mGPS scores were associated with lower 5-year recompensation rates (all P < 0.0001). Cox regression analysis revealed that in the fully adjusted model, GPS (HR: 0.311, 95% CI: 0.219-0.444), mGPS (HR: 0.302, 95% CI: 0.188-0.487), and hs-mGPS (HR: 0.351, 95% CI: 0.248-0.496) were all independent predictors for recompensation. Time-dependent ROC analysis showed that the AUCs for predicting recompensation were 0.888 for GPS, 0.795 for mGPS, and 0.871 for hs-mGPS, indicating the best predictive performance for GPS. Sensitivity and subgroup analyses confirmed the robustness of these findings. Conclusion: The GPS and its variants reliably predict recompensation in decompensated PBC, with the GPS showing superior accuracy. These tools can stratify risk and inform early intervention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.